1. Home
  2. DAWN vs DK Comparison

DAWN vs DK Comparison

Compare DAWN & DK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DAWN
  • DK
  • Stock Information
  • Founded
  • DAWN 2018
  • DK 2001
  • Country
  • DAWN United States
  • DK United States
  • Employees
  • DAWN N/A
  • DK N/A
  • Industry
  • DAWN Biotechnology: Pharmaceutical Preparations
  • DK Integrated oil Companies
  • Sector
  • DAWN Health Care
  • DK Energy
  • Exchange
  • DAWN Nasdaq
  • DK Nasdaq
  • Market Cap
  • DAWN 1.3B
  • DK 1.0B
  • IPO Year
  • DAWN 2021
  • DK 2006
  • Fundamental
  • Price
  • DAWN $12.79
  • DK $15.93
  • Analyst Decision
  • DAWN Strong Buy
  • DK Sell
  • Analyst Count
  • DAWN 7
  • DK 10
  • Target Price
  • DAWN $36.17
  • DK $21.22
  • AVG Volume (30 Days)
  • DAWN 1.0M
  • DK 1.1M
  • Earning Date
  • DAWN 10-30-2024
  • DK 11-06-2024
  • Dividend Yield
  • DAWN N/A
  • DK 6.40%
  • EPS Growth
  • DAWN N/A
  • DK N/A
  • EPS
  • DAWN N/A
  • DK N/A
  • Revenue
  • DAWN $101,953,000.00
  • DK $13,870,800,000.00
  • Revenue This Year
  • DAWN N/A
  • DK N/A
  • Revenue Next Year
  • DAWN $36.10
  • DK N/A
  • P/E Ratio
  • DAWN N/A
  • DK N/A
  • Revenue Growth
  • DAWN N/A
  • DK N/A
  • 52 Week Low
  • DAWN $11.94
  • DK $15.36
  • 52 Week High
  • DAWN $18.07
  • DK $33.60
  • Technical
  • Relative Strength Index (RSI)
  • DAWN 39.97
  • DK 33.59
  • Support Level
  • DAWN $12.26
  • DK $16.35
  • Resistance Level
  • DAWN $12.81
  • DK $17.83
  • Average True Range (ATR)
  • DAWN 0.52
  • DK 0.88
  • MACD
  • DAWN -0.05
  • DK -0.31
  • Stochastic Oscillator
  • DAWN 28.94
  • DK 1.20

About DAWN Day One Biopharmaceuticals Inc.

Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, kinase inhibitor.

About DK Delek US Holdings Inc.

Delek US Holdings Inc is an integrated energy business focused on petroleum refining, transportation and storage; wholesale crude oil, intermediate, and refined products, and convenience stores retailing. The company owns and operates independent refineries that produce a variety of petroleum products for transportation and industrial markets in the United States. Delek's logistics segment sells portions of the petroleum products its refineries produce. The logistics segment generates revenue through gathering, transporting, and storing crude oil and intermediate products, as well as by marketing, storing, and distributing refined products. The company also offers a collection of retail fuel and convenience stores operating in the Southeast region of the United States.

Share on Social Networks: